������������������

���������������������

�������������������������������

������ ����������

� ��������

��������� ������

The perfect Masterclass

FRIDAY, 19TH JUNE 2020 Scientific Program

07:30h Opening of registration desk

08:30-08:40h Opening lecture

08:40-09:10h Epidemiology and Etiology

• Natural history of PCa and it’s risk factors

• Biomarkers in prostate cancer: Any good news?

• Genomics, radiomics and racial disparities in PCa. Where do we stand?

• Molecular subtypes of PCa

• My father had it, what about me? Hereditary prostate cancer

• Doctor, what should I eat/drink? Gleason vs ISUP grades: Was it necessary?

09:10-09:30h Pathology in Pca in 2020: Update and new trends

09:30-09:45h Screening

• Improving specificity of PSA screening: Serum and urine markers

• USPTF: Why are there no urologists in the room?

• The harms of no screening

• Europe vs. the World (ERPCG vs. PLCO)

• I’m 45, can I get my PSA results, please?

• Before biopsy: What to do?

09:45-10:30h Diagnosis and Staging

• Biomarkers

• Liquid Biopsy

• Classic biopsy: Should we still do it? Fusion and systematic biopsy – The new standard?

• Targeted biopsy techniques and mpMRI-guided biopsy

• How to interpret multi-parametric MRI for improving diagnostic and therapeutic procedures

• MRI-targeted fusion biopsies: Are random biopsies still useful? Cognitive versus software-based fusion

• Do I really need a prostate biopsy?

• How long till my next biopsy?

• Patient tailored staging? Adequate?

• Which imaging method after initial prostate cancer diagnosis?

• Role of PSMA in PCa: A new standard? Primary. Recorrent

• PSMA – Diagnostic and therapeutic potential

10:30-11:00h Coffee break

11:00-12:15h Tumor Board: Localised Disease

• Not-so-active surveillance? When to skip biopsy. Which patient suits best?

• Radiotherapy vs. Surgery: Head to head discussion

• Brachytherapy for all of you, low and intermediate risk guys?

• Surgical steps for better oncological and functional outcomes

• The optimal candidate for local treatment

• Radical prostatectomy: Open? Robotic? Lap: Lost in the middle?

• PLND: Big or huge?

• How different is LND in prostate cancer from other pelvic diseases?

• Management of clinically node positive patients

• Positive margins after radical prostatectomy. Now what?

• Focal therapy – Ready for prime time? (Follow-up, complications, redo cases)

• Focal therapy – Are they all alike? (Cryosurgery, brachytherapy, HIFU, irreversible electroporation, interstitial laser and photodynamic therapy) Only experimental?

• How to select patients for good focal treatment (Pre-therapy criteria, energies, etc…)

12:15-12:45h Locally advanced disease

• Is there a role for surgery and salvage lymph node dissection?

• Positive margins after surgery? What do to do?

• Management of lymph node – Positive PCa

• Neoadjuvant systemic therapy in localized PCa – Back in?

• Active surveillance: As the jury returned?

• Management

12:45-13:15h Oligometastatic disease

• What on earth is oligometastatic disease?

• Oligometastatic Disease: Surgery? RT?

• Cytoreductive radical prostatectomy (M1 disease) – Grows or inhibits metastasis?

13:15-14:30h Lunch

14:30-15:00h Recurrent prostate cancer

• Where did it recur to?

• Biochemical and loco-regional recurrence: Now what?

• Brachytherapy boost with adjuvant radiotherapy; Who and when?

• Failure after focal therapy. Is it peanuts?

• Treatment of local recurrent PCa (whole gland cryotherapy, HIFU)

15:00-15:30h Non-metastatic Castration Resistant Prostate Cancer

• nmCRPC and mCRPC: Diagnostic workup

• Non-metastatic prostate cancer: Recent advancements, novel agents

15:30-16:15h Metastatic Hormone Sensitive Prostate Cancer

• Update on trial results and new trends in mHSPC

• Chemo-hormone treatment in mHSPC

• Management of metastatic prostate cancer: Tips and tricks

• The role of bone-protective agents. When, how and which?

• Hormone-naive metastatic disease first: What should I do?

16:15-16:40h Coffee break

16:40-17:40h Metastatic Castration Resistant Prostate Cancer

• It is now not that naïve: Hormone-resistant prostate cancer: What happened, what should I do?

• mCRPC: Which drugs? What sequence?

• Sequencing treatments in mCRPC – Uncharted territory

• Current management of bone-only metastatic prostate cancer

• Non-urological management of CRPC

17:40-18:00h New benchmarks for radical prostatectomy

• Outpatient prostatectomy

• Retzius sparing trans-douglas radical prostatectomy

• LESS for PCa

SATURDAY, 20TH JUNE 2020 Scientific Program

08:00h Opening of registration desk

08:30-09:00h Follow-up: Castrated and non-castrated patients

• Castrated patients: How to follow-up?

• Oncologic, continence, sexual function, bone health, cardiovascular disease, metabolic syndrome

• How to address cancer co-comorbities

09:00-09:30h Management of complications after primary treatment

• Treatment of radiation stricture – The ultimate guide

• Treatment of bladder neck stricture

• Incontinence treatment: New slings? Stick to the old ones?

• ED treatment after RP and RT

• Orgasmic dysfunction after RP, RT and BT

• Treatment of climaturia

09:30-10:45h Hot, Hot, Hot

• Hot Topics ASCO 2020

• Hot Topics EAU 2020

• Hot Topics AUA 2020

• Hot Topics ESMO 2020

• Hot Topics ASTRO and ESTRO 2020

10:45-11:15h Coffee break

11:15-11:45h Not so hot, still interesting

• Testosterone in prostate cancer: Fuel or brake?

• Is the castrate-resistant prostate cancer an oncologist disease?

• Managing of BPH in active surveillance patients

• PET-PSMA vs. scintigraphy: Is my algorithm all messed up?

• Circulating Tumor cells – What does it mean and how long to be using it in our clinic

• Is there a role for social media in prostate cancer? (Movember 2019? P-Race 2019?)

11:45-12:15h Emerging therapies

• Role of immunotherapy in advanced prostate cancer: Are we there yet

• Role of androgen receptor blockers in advanced prostate cancer

• Role of radiomics on PCa

• Role of PARPs and other novel pathways

• Targeting DNA repair deficiency in PCa

• Role of chemotherapy and radiopharmaceuticals in the management and treatment of advanced prostate cancer

12:15-12:45h Learning and self-assessment

12:45-13:00h Farewell message

Organizing Committee

José Santos DiasSandro GasparTiago OliveiraTomé Lopes

Organization

Secretariat

CMYK0/80/96/0 #5d40322/16/85/0 #fbd14266/79/89/26 #5d4032

Registrations online at www.admedic.pt

Calçada de Arroios, 16 C, Sala 3 1000-027 LisboaT: +351 21 842 97 10E: elsa.sousa@admedic.ptW: www.admedic.pt

EARLY FEEUntil December 31st,2019

REGULAR FEEUntil May, 19th, 2020

LATE FEEUntil June 12th,2020

ONSITE

Specialists 400 € 550 € 650 € 750 €

Residents* 250 € 400 € 500 € 550 €

Other healthcare professionals

200 € 300 € 400 € 450 €

*Written confirmation necessary to verify your resident status.

Scientific Committee

Antonio Lopez-Beltran (ES)Karim Touijer (USA)José Santos Dias (PT)Josep Maria Gaya (ES)Miguel Srgougi (BR)Sandro Gaspar (PT)Steven Joniau (BE)Tiago Oliveira (PT)Tomé Lopes (PT)